Healthcare / Medical DevicesKOSDAQ
$3270.00
-80.00 (-2.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $3.1B · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$84.1B
P/E
21.7x
↑EV/EBITDA
13.0x
↑ROE
5.5%
↑Gross Margin
48.7%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.6%
FCF CAGR
—
FCF margin
-2.6%
FCF / Net income
-0.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.82B · net income $3.89B · FCF $-796.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $30.82B | $30.82B | $31.70B | $29.81B | $27.69B |
| Net Income | $3.89B | $3.89B | $3.15B | $5.17B | $2.81B |
| EBITDA | $5.88B | $5.88B | $4.58B | $5.10B | $4.46B |
| EPS | 151.00 | 151.00 | 122.00 | 214.00 | 90.90 |
| Gross Margin | 48.7% | 48.7% | 52.2% | 52.5% | 51.0% |
| Operating Margin | -0.5% | -0.5% | 10.3% | 11.2% | 9.0% |
| Net Margin | 12.6% | 12.6% | 9.9% | 17.3% | 10.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.05 | 0.05 | 0.23 |
| Current Ratio | 11.96 | 11.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-796.9M | $-796.9M | $3.76B | $3.10B | $-309.8M |
| Returns | |||||
| ROE | 5.5% | 5.5% | 4.9% | 8.6% | 8.3% |
| Valuation | |||||
| P/E | 21.66 | 21.66 | 34.30 | 32.57 | 22.07 |
| EV/EBITDA | 13.03 | 13.03 | 21.24 | 31.75 | 14.69 |
| P/B | 1.18 | 1.18 | 1.69 | 2.80 | 1.84 |
| Growth & Yield | |||||
| Revenue Growth | -2.8% | -2.8% | 6.3% | 7.7% | — |
| EPS Growth | 23.8% | 23.8% | -43.0% | 135.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
24.3%
EPS terminal req.
$290.16
Spread vs growth
-0.6%
5Y implied EPS CAGR
18.4%
EPS terminal req.
$351.09
Spread vs growth
5.4%
10Y implied EPS CAGR
14.1%
EPS terminal req.
$565.44
Spread vs growth
9.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.6%
Start / end P/E
38.6x → 21.7x
EPS bridge
122.00 → 151.00
Residual
-10.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.